Comparison of long-term outcomes of 50 and 100mg rt-PA in the management of acute pulmonary thromboembolism


YILMAZEL UÇAR E. , ARAZ Ö. , KERGET B. , YILMAZ N. , AKGÜN M. , SAĞLAM L.

CLINICAL RESPIRATORY JOURNAL, vol.12, no.4, pp.1628-1634, 2018 (Journal Indexed in SCI) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1111/crj.12721
  • Title of Journal : CLINICAL RESPIRATORY JOURNAL
  • Page Numbers: pp.1628-1634
  • Keywords: long-term outcomes, pulmonary thromboembolism, thrombolytic therapy, DEEP-VEIN THROMBOSIS, PLASMINOGEN-ACTIVATOR, THROMBOLYTIC THERAPY, ANTITHROMBOTIC THERAPY, EUROPEAN-SOCIETY, TASK-FORCE, EMBOLISM, DIAGNOSIS, RISK, HYPERTENSION

Abstract

BackgroundPulmonary thromboembolism (PTE) is a life-threatening disease. In this study, we aimed to evaluate long-term outcomes of the use of 50mg recombinant tissue-type plasminogen activator (rt-PA) in the management of PTE in terms of relapse, pulmonary hypertension (PH), mortality and hemorrhage and to compare with the use of 100mg rt-PA.